Purple Biotech Ltd. Updates Company Presentation
Ticker: PPBT · Form: 6-K · Filed: Jun 4, 2024 · CIK: 1614744
Sentiment: neutral
Topics: company-update, investor-relations
TL;DR
Purple Biotech dropped a new investor deck on their site, check Exhibit 99.1.
AI Summary
On June 4, 2024, Purple Biotech Ltd. announced it has made an updated Company Presentation available on its website. This presentation is attached as Exhibit 99.1 to the filing.
Why It Matters
Investors can access the latest information about the company's strategy, progress, and future outlook through this updated presentation.
Risk Assessment
Risk Level: low — This filing is an informational update and does not contain significant financial or operational news.
Key Players & Entities
- Purple Biotech Ltd. (company) — Filer and subject of the announcement
- Exhibit 99.1 (document) — The updated Company Presentation
FAQ
What is the purpose of this 6-K filing?
The purpose of this 6-K filing is to announce that Purple Biotech Ltd. has made an updated Company Presentation available on its website.
When was the updated Company Presentation made available?
The updated Company Presentation was made available on June 4, 2024.
Where can the updated Company Presentation be found?
The updated Company Presentation is available on Purple Biotech Ltd.'s website and is attached to the filing as Exhibit 99.1.
What is the Commission File Number for Purple Biotech Ltd.?
The Commission File Number for Purple Biotech Ltd. is 001-37643.
What is the principal executive office address for Purple Biotech Ltd.?
The principal executive office address for Purple Biotech Ltd. is 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel.
Filing Stats: 545 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2024-06-04 16:00:54
Filing Documents
- ea0207312-6k_purplebio.htm (6-K) — 15KB
- ea020731201ex99-1_purplebio.htm (EX-99.1) — 72KB
- ex99-1_001.jpg (GRAPHIC) — 332KB
- ex99-1_002.jpg (GRAPHIC) — 793KB
- ex99-1_003.jpg (GRAPHIC) — 292KB
- ex99-1_004.jpg (GRAPHIC) — 334KB
- ex99-1_005.jpg (GRAPHIC) — 330KB
- ex99-1_006.jpg (GRAPHIC) — 446KB
- ex99-1_007.jpg (GRAPHIC) — 397KB
- ex99-1_008.jpg (GRAPHIC) — 426KB
- ex99-1_009.jpg (GRAPHIC) — 467KB
- ex99-1_010.jpg (GRAPHIC) — 337KB
- ex99-1_011.jpg (GRAPHIC) — 418KB
- ex99-1_012.jpg (GRAPHIC) — 365KB
- ex99-1_013.jpg (GRAPHIC) — 316KB
- ex99-1_014.jpg (GRAPHIC) — 375KB
- ex99-1_015.jpg (GRAPHIC) — 329KB
- ex99-1_016.jpg (GRAPHIC) — 341KB
- ex99-1_017.jpg (GRAPHIC) — 424KB
- ex99-1_018.jpg (GRAPHIC) — 284KB
- ex99-1_019.jpg (GRAPHIC) — 279KB
- ex99-1_020.jpg (GRAPHIC) — 387KB
- ex99-1_021.jpg (GRAPHIC) — 369KB
- ex99-1_022.jpg (GRAPHIC) — 456KB
- ex99-1_023.jpg (GRAPHIC) — 425KB
- ex99-1_024.jpg (GRAPHIC) — 367KB
- ex99-1_025.jpg (GRAPHIC) — 321KB
- ex99-1_026.jpg (GRAPHIC) — 376KB
- ex99-1_027.jpg (GRAPHIC) — 299KB
- ex99-1_028.jpg (GRAPHIC) — 289KB
- ex99-1_029.jpg (GRAPHIC) — 444KB
- ex99-1_030.jpg (GRAPHIC) — 299KB
- ex99-1_031.jpg (GRAPHIC) — 372KB
- ex99-1_032.jpg (GRAPHIC) — 294KB
- ex99-1_033.jpg (GRAPHIC) — 290KB
- ex99-1_034.jpg (GRAPHIC) — 236KB
- ex99-1_035.jpg (GRAPHIC) — 343KB
- ex99-1_036.jpg (GRAPHIC) — 336KB
- ex99-1_037.jpg (GRAPHIC) — 345KB
- ex99-1_038.jpg (GRAPHIC) — 418KB
- ex99-1_039.jpg (GRAPHIC) — 359KB
- ex99-1_040.jpg (GRAPHIC) — 382KB
- ex99-1_041.jpg (GRAPHIC) — 373KB
- ex99-1_042.jpg (GRAPHIC) — 133KB
- ex99-1_043.jpg (GRAPHIC) — 256KB
- ex99-1_044.jpg (GRAPHIC) — 259KB
- ex99-1_045.jpg (GRAPHIC) — 384KB
- ex99-1_046.jpg (GRAPHIC) — 347KB
- ex99-1_047.jpg (GRAPHIC) — 248KB
- ex99-1_048.jpg (GRAPHIC) — 420KB
- ex99-1_049.jpg (GRAPHIC) — 313KB
- ex99-1_050.jpg (GRAPHIC) — 284KB
- ex99-1_051.jpg (GRAPHIC) — 426KB
- ex99-1_052.jpg (GRAPHIC) — 396KB
- 0001213900-24-049647.txt ( ) — 25610KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. June 4, 2024 PURPLE BIOTECH LTD. By: /s/ Lior Fhima Lior Fhima Chief Financial Officer 2